Patient P-02451
Therapy response
Improving
Tolerance
Improving
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Improving
Discontinuation risk
6%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S08
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Treatment adherence+5
- Toxicity-5
- GI instability-4
- Nutritional resilience+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable56 min
worsening · -3.4 vs previous 14 d
Sleep duration
Wearable7.3 h
stable · +0.1 vs previous 14 d
Energy level
Daily log7.2/10
improving · +0.4 vs previous 14 d
Steps
Wearable5,336
stable · -103 vs previous 14 d
GI burden
Companion16/100
improving · -2.5 vs previous 14 d
Adherence
Companion99.1 %
improving · +8.1 vs previous 14 d
Sleep quality
Wearable58.3/100
stable · +2.1 vs previous 14 d
Glucose, CGM daily mean
CGM128 mg/dL
stable · +1.6 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 91 from the failing basin, 7 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +5.5
- Proteinsupporter · GI -3.2 next day
Main detractors to watch
- FUT2 non-secretorhidden · steering -10.6
- Bacteroides fragilis elevatedhidden · steering -7.4
- Histamine loadperturbation · steering -6.8
- Antibiotic courseperturbation · steering -4.7
- Histamine loaddetractor · GI +3.8 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+3.8detractor · 95%
- Protein-3.2supporter · 95%
- Ultra-processed food-1.5no signal · 44%
- Insoluble fibre-0.7no signal · 21%
- Simple carbohydrates-0.5no signal · 15%
- Alcohol-0.3no signal · 15%
- Dietary fat load-0.1no signal · 15%
- Caffeine-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↓25
- WearableResting HR 73 bpm
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 4.4 · butyrate capacity 62/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 64 ms
- Sleep
- 7.2 h
- Steps
- 4,539
- Resting HR
- 72 bpm
Daily log: GI score 16, nutritional resilience 68, adherence 99.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02486 | 52% | S10 | ME-01 | improved | 86 |
| P-02277 | 47% | S05 | AD-05 | improved | 92 |
| P-02127 | 45% | S11 | SC-12 | improved | 73 |
| P-02450 | 44% | S12 | NP-02 | improved | 92 |
| P-02667 | 43% | S08 | HY-01 | improved | 77 |
| P-02464 | 42% | S18 | ME-01 | improved | 68 |
| P-02068 | 41% | S14 | NP-02 | improved | 83 |
| P-02193 | 40% | S11 | CR-01 | improved | 87 |
| P-02249 | 40% | S09 | DT-01 | improved | 100 |
| P-02630 | 40% | S17 | NP-02 | improved | 76 |
| P-02415 | 38% | S17 | GI-04 | improved | 86 |
| P-02690 | 38% | S02 | ME-01 | improved | 73 |